Simplex Trading’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.88K Sell
14,000
-109,600
-89% -$47.4K ﹤0.01% 8203
2025
Q4
$195K Buy
123,600
+108,300
+708% +$173K ﹤0.01% 4258
2025
Q3
$16K Sell
15,300
-4,100
-21% -$7.09K ﹤0.01% 7544
2025
Q2
$31K Sell
19,400
-700
-3% -$1.12K ﹤0.01% 6375
2025
Q1
$24K Sell
20,100
-159,400
-89% -$279K ﹤0.01% 6434
2024
Q4
$339K Buy
179,500
+172,000
+2,293% +$708K ﹤0.01% 3934
2024
Q3
$40K Buy
7,500
+7,100
+1,775% +$52K ﹤0.01% 6089
2024
Q2
$2K Buy
+400
New +$3.21K ﹤0.01% 8327

Other funds holding OTLK

Simplex Trading's OTLK Position: Q1 2026 in Review

Simplex Trading increased its Outlook Therapeutics (OTLK) stake by 25% in Q1 2026, buying an estimated $11.6K and bringing the position to 132,666 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6483.

Simplex Trading first reported a position in OTLK in Q2 2024 and has held it in 4 quarters since. The position peaked at $167K in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Simplex Trading held 132,666 shares of Outlook Therapeutics worth $27.3K as of Q1 2026.
  • Simplex Trading bought 26,869 Outlook Therapeutics shares in Q1 2026, an estimated $11.6K.
  • Outlook Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6483 holding.
  • Simplex Trading first reported a position in Outlook Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Simplex Trading's Outlook Therapeutics position peaked at $167K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.